In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results